JP2024510666A - Ddr遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ - Google Patents

Ddr遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ Download PDF

Info

Publication number
JP2024510666A
JP2024510666A JP2023557691A JP2023557691A JP2024510666A JP 2024510666 A JP2024510666 A JP 2024510666A JP 2023557691 A JP2023557691 A JP 2023557691A JP 2023557691 A JP2023557691 A JP 2023557691A JP 2024510666 A JP2024510666 A JP 2024510666A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
administered
talazoparib
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510666A5 (cg-RX-API-DMAC7.html
Inventor
ガボー ズィベレ アコス
アン ケネディー ダナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JP2024510666A publication Critical patent/JP2024510666A/ja
Publication of JP2024510666A5 publication Critical patent/JP2024510666A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023557691A 2021-03-24 2022-03-21 Ddr遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ Pending JP2024510666A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163165723P 2021-03-24 2021-03-24
US63/165,723 2021-03-24
US202163282163P 2021-11-22 2021-11-22
US63/282,163 2021-11-22
US202263317368P 2022-03-07 2022-03-07
US63/317,368 2022-03-07
PCT/IB2022/052536 WO2022200982A1 (en) 2021-03-24 2022-03-21 Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer

Publications (2)

Publication Number Publication Date
JP2024510666A true JP2024510666A (ja) 2024-03-08
JP2024510666A5 JP2024510666A5 (cg-RX-API-DMAC7.html) 2025-03-31

Family

ID=80952181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557691A Pending JP2024510666A (ja) 2021-03-24 2022-03-21 Ddr遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ

Country Status (9)

Country Link
US (1) US20240180906A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313034A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024510666A (cg-RX-API-DMAC7.html)
KR (1) KR20230159510A (cg-RX-API-DMAC7.html)
AU (2) AU2022244439A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018906A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214316A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011294A (cg-RX-API-DMAC7.html)
WO (1) WO2022200982A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202600137A (zh) 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用parp抑制劑的治療作為預測性生物標記之tmprss2-erg和rbi及使用parp抑制劑之治療方法
WO2026078615A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078619A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020516646A (ja) * 2017-04-13 2020-06-11 ヤンセン ファーマシューティカ エヌ.ベー. 前立腺癌の併用療法
JP2020536887A (ja) * 2017-10-13 2020-12-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Parp阻害剤およびpd−1系結合アンタゴニストの組合せ

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
BRPI0709771B1 (pt) 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
NZ596260A (en) 2006-03-29 2013-05-31 Univ California Diarylthiohydantoin compounds
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
HUE035295T2 (en) 2008-08-06 2018-05-02 Medivation Technologies Inc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
JP2012518661A (ja) 2009-02-24 2012-08-16 メディベイション プロステイト セラピューティクス, インコーポレイテッド 特定のジアリールヒダントインおよびジアリールチオヒダントイン化合物
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
MX340319B (es) 2010-02-08 2016-07-06 Medivation Technologies Inc Procesos para sintetizar derivados de dihidropiridoftalazinona.
CN103282365B (zh) 2010-10-21 2017-12-29 麦迪韦逊科技有限公司 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
EP3066084A1 (en) 2013-11-07 2016-09-14 Medivation Technologies, Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
EA201790290A1 (ru) 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
CN108883115A (zh) 2015-10-26 2018-11-23 麦迪韦逊科技有限责任公司 用parp抑制剂治疗小细胞肺癌
US20210355223A1 (en) * 2018-11-05 2021-11-18 Pfizer Inc. Combinations for Treating Cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020516646A (ja) * 2017-04-13 2020-06-11 ヤンセン ファーマシューティカ エヌ.ベー. 前立腺癌の併用療法
JP2020536887A (ja) * 2017-10-13 2020-12-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Parp阻害剤およびpd−1系結合アンタゴニストの組合せ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV, JPN7026000862, 4 December 2020 (2020-12-04), ISSN: 0005811710 *
JOURNAL OF CLINICAL ONCOLOGY, vol. Vol. 38, No. 6_suppl., JPN7026000863, 19 February 2020 (2020-02-19), ISSN: 0005811711 *
THE ONCOLOGIST, vol. 25, JPN6026008234, 19 March 2020 (2020-03-19), pages 1042 - 1050, ISSN: 0005811712 *

Also Published As

Publication number Publication date
EP4313034A1 (en) 2024-02-07
KR20230159510A (ko) 2023-11-21
MX2023011294A (es) 2023-10-05
US20240180906A1 (en) 2024-06-06
AU2025210784A1 (en) 2025-08-21
AU2022244439A1 (en) 2023-09-28
WO2022200982A1 (en) 2022-09-29
BR112023018906A2 (pt) 2023-10-10
CA3214316A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
US20240180906A1 (en) Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer
EP3721906A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
JP2023537595A (ja) 併用治療
KR20150017367A (ko) 종양 질환을 치료하기 위한 17-알파-히드록실라제 (c17,20-리아제) 억제제와 특이적 pi-3k 억제제의 조합물
US20250090514A1 (en) Method of treating cancer
EP4633629A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
JP2025533012A (ja) 転移性去勢抵抗性前立腺癌の処置におけるタラゾパリブおよびエンザルタミドの組合せ
HK40098285A (en) Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
CN117098535A (zh) 用于治疗ddr基因突变转移性去势敏感性前列腺癌的他拉唑帕尼与抗雄激素的组合
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
HK40096012A (en) Combination therapy
WO2025210510A1 (en) Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor
WO2026078619A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078615A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2023114264A1 (en) Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
EA049014B1 (ru) Способ лечения рака
HK40046131A (en) Quinoline derivative used for treating small cell lung cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260804